GlassScriptPhysician profile
Eugenia Hahn
NPI 1285640458
$5,784.17
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $1,499 · 2021: $2,015 · 2022: $926.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $860.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $776.14 | 2019-2022 | |
| Alk-Abello, INC | $770.69 | 2019-2022 | |
| Csl Behring | $550.72 | 2019-2022 | |
| Covis Pharma Gmbh | $506.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $441.79 | 2020-2022 | |
| Genzyme Corporation | $410.34 | 2019-2022 | |
| Pfizer INC. | $256.95 | 2019-2022 | |
| Optinose US, INC. | $178.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $161.40 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $152.61 | 2019-2022 | |
| Kaleo, INC. | $84.56 | 2019-2021 | |
| Shire North American Group INC | $64.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.44 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $50.26 | 2019-2021 | |
| Octapharma USA, INC. | $41.39 | 2022 | |
| Grifols USA, LLC | $38.48 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $35.31 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $28.99 | 2020-2022 | |
| Amgen INC. | $24.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.02 | 2019 | |
| Merck Sharp & Dohme LLC | $20.56 | 2021 | |
| Hospira, INC. | $20.08 | 2022 | |
| Bio Products Laboratory USA, INC. | $18.27 | 2021 | |
| Phadia US INC. | $16.36 | 2020 | |
| Uswm, LLC | $15.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $14.78 | 2020 | |
| Philips North America LLC | $13.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenia Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.